Change Agents Corporation. (CHGA) · Oct 19, 2026 · Share issuance
62,000-share warrant — 62,000 shares at $0.0001 exercise price for waiver of repayment rights
Change Agents’ debt waiver keeps recent financing available, but the price is a new 62,000-share pre-funded warrant and added dilution risk.
Change Agents is a newly renamed Nasdaq company pivoting toward agentic-AI software and autonomous air-surveillance/C-UAS products, while still relying on outside capital to fund that transition. The filing keeps the latest financing available, but only by paying another equity-linked cost. The holder waives its right to require repayment from the $336,000 of notes issued around September 30, 2026, allowing those proceeds to remain with the company. 〔0〕
The consideration is a new claim on the equity. Change Agents must issue a pre-funded warrant for 62,000 common shares at a nominal $0.0001 exercise price. 〔1〕 That is not an operating milestone or cheaper capital; it is effectively a near-cashless path to additional shares for the lender.
The immediate business effect is liquidity preservation, not growth acceleration. The company avoids diverting the fresh note proceeds to repay an older note, which matters for a capital-hungry AI transition. But the filing also confirms that financing is becoming increasingly equity-linked: the warrant carries resale-registration rights, and issuance above Nasdaq’s 19.99% threshold may require shareholder approval.
The paperwork is more complicated than a routine waiver. The agreement identifies the holder through an unresolved bracketed alternative—“Dune Equity Holdings LLC” or “FirstFire Global Opportunities Fund LLC”—so the filed exhibit does not cleanly identify the counterparty. The company also says it will use reasonable best efforts to seek shareholder approval at its first meeting after the effective date. 〔2〕
Bottom line: This is a financing-liquidity positive but an expectation-negative capital-structure development: Change Agents retains recent cash for its AI buildout, while giving lenders another low-cost route into the equity. The event matters mainly because it shows the company is funding its transition through increasingly dilutive instruments, not because it changes the underlying product story.
Shareholder approval at the first meeting after October 4
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!